Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents

Population level survival of patients with myelodysplastic syndromes (MDS) treated with hypomethylating agents (HMA) is inferior to clinical trials. Using SEER-Medicare data, we identified 2,086 MDS patients diagnosed in 2004–13, aged ≥66 years at diagnosis, and receiving ≥1 HMA cycle. We used multi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leuk Lymphoma
Main Authors: Zeidan, Amer M., Hu, Xin, Zhu, Weiwei, Stahl, Maximilian, Wang, Rong, Huntington, Scott F., Giri, Smith, Bewersdorf, Jan Philipp, Podoltsev, Nikolai A., Gore, Steven D., Ma, Xiaomei, Davidoff, Amy J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7732188/
https://ncbi.nlm.nih.gov/pubmed/31570040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2019.1663423
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados